Latest Off-label use Stories
Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients â€” a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.
A new editorial article, published in the Canadian Medical Association Journal, suggests physicians should be more careful when prescribing drugs "off-label".
Top-selling drugs, known as atypical antipsychotic medications, lack evidence that theyâ€™ll actually be beneficial, according to a new study.
MUNICH, November 19, 2010 /PRNewswire/ -- Many of the medications used to treat children have been developed almost exclusively for adults and approved for them.
More than 17,000 healthcare providers, including doctors, have received money from several major drug companies to talk to other doctors about their products.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
SHORT HILLS, N.J., Sept. 17 /PRNewswire/ -- Fresh off his victory for a whistle-blower in the Forest Pharmaceuticals, Inc.
Allergan Inc, maker of the popular Botox anti-wrinkle treatment, said on Wednesday that it had agreed to pay $600 million to settle an investigation into whether the company had illegally marketed the drug for off-label uses.
SILVER SPRING, Md., July 28 /PRNewswire-USNewswire/ --The U.S.
- A transitional zone between two communities containing the characteristic species of each.